By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Fulcrum Therapeutics 

One Kendall Square, Building 700
Suite B7102
Cambridge  Massachusetts  02139  U.S.A.
Phone: 617-651-8851 Fax: n/a


Fulcrum Therapeutics is a biotechnology company developing new medicines to deliver a new future to patients and their families by transforming gene regulation in disease. Fulcrum’s therapies are based on modulating gene regulation via control of genetic on and off switches of disease genes. Fulcrum was launched in 2016 by Third Rock Ventures, and is headquartered in Cambridge, Mass.


July 2016


CEO: Robert J. Gould, Ph.D.


Please click here for clinical trial information.

Key Statistics

Ownership: Private

Web Site: Fulcrum Therapeutics

Company News
Fulcrum Therapeutics Announces Additional Series A Financing From GV 5/10/2017 8:25:05 AM
Fulcrum Therapeutics Expands Leadership Team With Appointment Of Owen Wallace, Ph.D., As Chief Scientific Officer And Amit Hasija As Chief Business Officer 5/3/2017 8:48:53 AM
Fulcrum Therapeutics Strengthens Its Board Of Directors With The Addition Of Alan Ezekowitz, MBChB, D.Phil., And James J. Collins, Ph.D. 2/7/2017 6:53:42 AM
The Next Generation: Top 20 Life Science Startups to Watch in 2017 1/3/2017 3:19:44 PM
What You Need to Know About Fulcrum Therapeutics 1/3/2017 3:03:48 PM
Fulcrum Therapeutics Appoints Renowned Experts In CNS Disorders And Muscular Dystrophies To Serve On Newly Formed Scientific Advisory Board 12/7/2016 11:27:57 AM
Horizon Discovery Ltd. And Fulcrum Therapeutics Form Collaboration For Novel CRISPR-Based Target Discovery In Genetic Diseases 9/6/2016 11:22:39 AM
Former Epizyme (EPZM) CEO Helms Fulcrum Therapeutics; New Startup Banks $55 Million Series A 7/19/2016 6:01:46 AM